- Oncology-focused shares Ideaya Biosciences Inc IDJA are then traded higher intermediate data of its solid tumor candidate darovasertib with the cancer therapy crizotinib in patients with metastatic uveal melanoma (MUM).
- Interim results confirmed a partial response in four of eight evaluable patients or an overall response rate of 50% in patients with first-line metastatic uveal melanoma.
- 89% of patients showed tumor shrinkage in patients with metastatic uveal melanoma in each lineage, the company said.
- 15 of 35 evaluable patients observed a partial response with >30% tumor reduction, including 11 confirmed and four unconfirmed partial responses.
- 50% of the overall response rate was observed, with 4 of 8 evaluable patients having a confirmed partial response (PR).
- Meanwhile, the median progression-free survival in patients with first-line metastatic uveal melanoma has not yet been reached, while the median progression-free survival in patients with metastatic uveal melanoma of any line of treatment is approximately five months.
- The Company plans to initiate a potential registration enablement study in Q1 2023.
- Price promotion: IDYA shares are up 26.40% to $11.69 on Monday’s latest check.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
